Article citationsMore>>

S. R. Alberts, T. R. Fitch, G. P. Kim, B. W. Morlan, S. R. Dakhil, H. M. Gross and S. Nair, “Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial,” American Journal of Clinical Oncology, Vol. 35, No. 4, 2012, pp. 329-333. doi:10.1097/COC.0b013e3182118cdf

has been cited by the following article:

• TITLE: Molecular Targeted Therapy of Hepatocellular Carcinoma

  AUTHORS: Kimberly Terry, Mehmet Sitki Copur

  KEYWORDS: Hepatocellular Carcinoma (HCC); Treatment; Molecular Therapies; Novel Agents

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.2A, February 28, 2013

  ABSTRACT: Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related mortality worldwide. Despite decades of efforts by many investigators, systemic chemotherapy or hormonal therapy has notoriously failed to show an improvement in survival. With a median survival of 8 months, and 1- and 3-year survival rates of 20% and 5%, respectively, the effective treatment of HCC remains far from satisfactory. Better understanding of the pathogenesis of this disease, identification of molecular targets for therapeutic intervention and availability of promising molecularly targeted therapies may change this dismal picture. In this review we will focus on what is currently known about the molecular pathogenesis of HCC, and explore the currently available and future molecular based therapies targeting these pathways. Future research in this area will maximize clinical benefit while minimizing the toxicity and cost through utilization of novel targeted agents.